Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia
BEGUET-YACHINE, Mathilde
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
See more >
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
BEGUET-YACHINE, Mathilde
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
RATIARISON, Diana
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
TUMIOTTO, Camille
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Microbiologie Fondamentale et Pathogénicité [MFP]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Microbiologie Fondamentale et Pathogénicité [MFP]
LAFARGE, Xavier
Biothérapies des maladies génétiques et cancers
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
< Reduce
Biothérapies des maladies génétiques et cancers
Etablissement Français du Sang Nouvelle Aquitaine [Bordeaux] [EFS Bordeaux Nouvelle Aquitaine]
Language
EN
Article de revue
This item was published in
Journal of Medical Virology. 2021-05-03p. Online ahead of print
English Abstract
This study aims to assess the efficacy and safety of convalescent plasma therapy (CPT) in COVID-19 critically ill patients with protracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia. A retrospective ...Read more >
This study aims to assess the efficacy and safety of convalescent plasma therapy (CPT) in COVID-19 critically ill patients with protracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNAemia. A retrospective cohort study was conducted in intensive care unit (ICU). All patients with severe COVID-19 pneumonia for whom RNAemia remained positive more than 14 days after onset of the infection were included and given CPT. The primary objective was to evaluate SARS-CoV-2 RNAemia 7 days (D7) after CPT. A total of 14 patients were included and they received a median CPT volume of 828 ml (range: 817-960). CPT was administered in a median time of 14 days after ICU admission. At D7, 13/14 patients had negative SARS-CoV-2 blood PCR and one patient had negative blood PCR 11 days after CPT. At D7 and at D14, the clinical status was improved in 7/14 and 11/14 patients, respectively. The 28-day mortality rate was 14%. No CPT-related adverse effects had been reported. CPT is safe and may be efficient in patients with protracted RNAemia admitted in ICU for severe COVID-19 pneumonia. Randomized controlled trials are needed to confirm these results.Read less <
English Keywords
Combination therapy
Disease control
Generalized infection
Pathogenesis
SARS coronavirus
Virus classification